Skip to main content
OpenTrials
Completed

NCT Number: NCT07167511

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Helicobacter Pylori Infection

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients aged 18-70 years, regardless of gender;
  • absent history of receiving H. pylori eradication therapy;
  • diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion criteria

  • patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
  • patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Treatment and study plan

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Other

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Primary outcomes

  1. Eradication rate

    Time frame: 6 weeks after treatment completion

    Comparison of eradication rates among quadruple therapies for Helicobacter pylori

Secondary outcomes

  1. Adverse events

    Time frame: Immediately after treatment completion

Sponsors and collaborators

Lead sponsor

Yueyue Li

Other

Collaborators

  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
  • Dezhou Hospital Qilu Hospital of Shandong University
  • Qihe County People's Hospital
  • Qilu Hospital of Shandong University
  • Shandong University of Traditional Chinese Medicine
  • Taierzhuang District People's Hospital
  • Zaozhuang Municipal Hospital

Registry information

Official study title

Efficacy and Safety of Bismuth-containing Quadruple Therapy for First Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study

Acronym: RETRO-HP

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
Sep 11, 2025
Registry last updated
Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.